Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines.

作者: David G. Hicks , Raymond R. Tubbs

DOI: 10.1016/J.HUMPATH.2004.11.010

关键词:

摘要: Diagnostic assays for HER2 in breast cancer provide important prognostic information and independently help guide management by identifying patients who are the most likely to benefit from Herceptin-targeted therapy. The biological events underlying -driven that can be assessed routine clinical specimens include evaluation of gene amplification fluorescence situ hybridization (FISH), enhanced messenger RNA expression real-time polymerase chain reaction, assessment protein overexpression at tumor cell membrane immunohistochemistry (IHC). Immunohistochemistry FISH methodologies have advantage being morphologically driven, allowing correlations between morphologic features. However, each has advantages disadvantages, which discussed detail. Although is familiar readily accommodated surgical pathology laboratories, increasing demands testing setting will require greater familiarity with technical aspects their interpretation laboratory community. In this review, we an overview cancer, emphasis on considerations, interpretive guidelines, scoring criteria, quality control. development automated platforms hybridization, image analysis signal enumeration, experience should broaden availability technology diagnostic testing.

参考文章(53)
John M. S. Bartlett, Fluorescence In Situ Hybridization Methods in molecular medicine. ,vol. 97, pp. 77- 87 ,(2004) , 10.1385/1-59259-760-2:077
Raymond Tubbs, James Pettay, Marek Skacel, Richard Powell, Mark Stoler, Patrick Roche, James Hainfeld, Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification. American Journal of Pathology. ,vol. 160, pp. 1589- 1595 ,(2002) , 10.1016/S0002-9440(10)61106-6
John M. S. Bartlett, Amanda Forsyth, HER2 FISH in breast cancer. Methods in molecular medicine. ,vol. 97, pp. 89- 101 ,(2004) , 10.1385/1-59259-760-2:089
Suzanne A. Eccles, The Role of c-erbB-2/HER2/neu in Breast Cancer Progression and Metastasis Journal of Mammary Gland Biology and Neoplasia. ,vol. 6, pp. 393- 406 ,(2001) , 10.1023/A:1014730829872
Michael F. Press, Dennis J. Slamon, Kerry J. Flom, Jinha Park, Jian-Yuan Zhou, Leslie Bernstein, Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens Journal of Clinical Oncology. ,vol. 20, pp. 3095- 3105 ,(2002) , 10.1200/JCO.2002.09.094
Luis Alberto Rubio-Martinez, José Maria Vera-Roman, Comparative assays for the HER-2/neu oncogene status in breast cancer. Archives of Pathology & Laboratory Medicine. ,vol. 128, pp. 627- 633 ,(2004) , 10.1043/1543-2165(2004)128<627:CAFTNO>2.0.CO;2
Jennet M. Harvey, Gary M. Clark, C. Kent Osborne, D. Craig Allred, Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer Journal of Clinical Oncology. ,vol. 17, pp. 1474- 1474 ,(1999) , 10.1200/JCO.1999.17.5.1474
R.R. Tubbs, J.D. Pettay, P.C. Roche, M.H. Stoler, R.B. Jenkins, T.M. Grogan, Discrepancies in Clinical Laboratory Testing of Eligibility for Trastuzumab Therapy: Apparent Immunohistochemical False-Positives Do Not Get the Message Journal of Clinical Oncology. ,vol. 19, pp. 2714- 2721 ,(2001) , 10.1200/JCO.2001.19.10.2714
S Toikkanen, H Helin, J Isola, H Joensuu, Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. Journal of Clinical Oncology. ,vol. 10, pp. 1044- 1048 ,(1992) , 10.1200/JCO.1992.10.7.1044